AIkido Pharma Announces Share Repurchase Program

NEW YORK, Jan. 24, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI ) ("AIkido" or the "Company"), a clinical and early-stage drug development company, today announced that its board of directors (the "Board") has authorized a share repurchase program to repurchase up to $3 million of the Company's outstanding common stock. The share repurchase authorization is effective immediately.

Read more at prnewswire.com